All included studies contained patients diagnosed with NSCLC or lung adenocarcinoma harboring driver genes including EGFR, ALK, ROS1, KRAS, MET and BRAF. All included studies were of good quality, as assessed using the Newcastle-Ottawa quality assessment scale for cohort and case-control studies (Supplementary Table 2). This evidence concerns the gene BRAF and non-small cell lung carcinoma.